Related Experiment Video
Updated: Jun 19, 2026
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
In vivo model of pseudomyxoma peritonei for novel candidate drug discovery
Terence C Chua1, Javed Akther, Peng Yao
1Department of Surgery, University of New South Wales, St. George Hospital, Kogarah, Sydney, NSW 2217, Australia.
Abstract:
Pseudomyxoma peritonei (PMP) is a clinical condition characterized by diffuse intraabdominal spread of mucinous tumor implants that form on peritoneal surfaces. To complement the efficacy of cytoreductive surgery, an effective cytotoxic drug is required as an intraperitoneal agent for microscopic cytoreduction locoregionally. To develop a model for drug discovery, human pseudomyxoma peritonei tumor implants consisting of a mixture of mucin and epithelial cells were injected into the peritoneal cavity of CBH/rnu/rnu rats. A fixed quantity of tumor (2 ml) was implanted in each of the 9 male rats. Over 90 days, all rats developed PMP indicating that this in vivo animal model may become useful platform in a drug discovery program to allow drug efficacy testing against human PMP.
Insights
Researchers developed a new animal model for pseudomyxoma peritonei (PMP) by implanting human PMP tumors in rats. This model is crucial for testing new drugs to treat PMP effectively.
Area of Science:
- Oncology
- Surgical Oncology
- Preclinical Research
Background:
- Pseudomyxoma peritonei (PMP) is characterized by widespread mucinous tumor implants on peritoneal surfaces.
- Cytoreductive surgery for PMP requires effective intraperitoneal cytotoxic agents for microscopic disease.
- There is a need for reliable preclinical models to test novel drug therapies for PMP.
Purpose of the Study:
- To develop and validate an in vivo animal model for human pseudomyxoma peritonei (PMP).
- To establish a platform for preclinical drug discovery and efficacy testing against PMP.
Main Methods:
- Human PMP tumor implants (mucin and epithelial cells) were injected into the peritoneal cavity of CBH/rnu/rnu rats.
- A fixed volume (2 ml) of tumor was implanted in each of the 9 male rats.
- Tumor development was monitored over 90 days.
Main Results:
- All 9 rats successfully developed PMP within 90 days.
- The model demonstrated successful engraftment and spread of human PMP tumors in an immunocompromised rat model.
- This indicates the model's suitability for further study.
Conclusions:
- The developed rat model effectively replicates human pseudomyxoma peritonei.
- This preclinical model serves as a valuable platform for evaluating the efficacy of novel intraperitoneal drugs for PMP treatment.
- It facilitates the advancement of drug discovery programs for PMP.
